Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report, dated October 17, 2025, covers the month of October 2025 for Haoxi Health Technology Limited, a foreign private issuer headquartered in Beijing, China. The filing discloses the entry into a material definitive agreement regarding a private placement of securities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial metric disclosed relates to the private placement transaction:
- Offering Proceeds: Approximately $1.2 million aggregate purchase price.
- Shares Issued: 5,217,391 Class A ordinary shares.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes
On October 13, 2025, the Company entered into a Securities Purchase Agreement (SPA) with certain "non-U.S. Persons" under Regulation S. This transaction represents a material change in the Company's capital structure and liquidity position pending closing conditions.
Outlook, Risks, and Contingencies
The closing of the offering is subject to various conditions, including the accuracy of representations and warranties made by the parties. The shares are exempt from registration requirements under Regulation S. The filing notes customary representations regarding the absence of undisclosed material adverse effects and legal proceedings affecting the transaction. No specific forward-looking guidance or management commentary on future operations is provided in this text.
Investor Verification Checklist
- Verify the final closing of the $1.2 million private placement and the actual receipt of proceeds.
- Confirm the identity of the "non-U.S. Persons" purchasing the shares.
- Review the full Securities Purchase Agreement (Exhibit 99.1) for specific covenants and conditions to closing.
- Monitor subsequent filings for updated financial statements reflecting the new capital.